These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 8528055

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
    Silla LM, Pincus SM, Locker JD, Glover J, Elder EM, Donnenberg AD, Nardi NB, Bryant J, Ball ED, Whiteside TL.
    Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
    Nieda M, Nicol A, Kikuchi A, Kashiwase K, Taylor K, Suzuki K, Tadokoro K, Juji T.
    Blood; 1998 Feb 01; 91(3):977-83. PubMed ID: 9446659
    [Abstract] [Full Text] [Related]

  • 6. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
    Yasukawa M, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, Hirai H, Fujita S.
    Blood; 2001 Sep 01; 98(5):1498-505. PubMed ID: 11520800
    [Abstract] [Full Text] [Related]

  • 7. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC, Hsiao MH, Pattengale PK.
    Nat Immun Cell Growth Regul; 1991 Sep 01; 10(2):57-70. PubMed ID: 1881400
    [Abstract] [Full Text] [Related]

  • 8. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia.
    Wagner WM, Ouyang Q, Pawelec G.
    Leukemia; 2002 Nov 01; 16(11):2341-3. PubMed ID: 12399986
    [No Abstract] [Full Text] [Related]

  • 9. [Study on T lymphocyte recognition of tumor antigens on autologous CML cells].
    Chen Y, Hao Y, You S, Wei D, Wei D, Liao X, Ding S, Liu S, Wei D.
    Zhonghua Xue Ye Xue Za Zhi; 1997 Dec 01; 18(12):638-41. PubMed ID: 15625763
    [Abstract] [Full Text] [Related]

  • 10. The role of autologous natural killer cells in chronic myelogenous leukemia.
    Pierson BA, Miller JS.
    Leuk Lymphoma; 1997 Nov 01; 27(5-6):387-99. PubMed ID: 9477121
    [Abstract] [Full Text] [Related]

  • 11. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
    Bosch GJ, Joosten AM, Kessler JH, Melief CJ, Leeksma OC.
    Blood; 1996 Nov 01; 88(9):3522-7. PubMed ID: 8896419
    [Abstract] [Full Text] [Related]

  • 12. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
    Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS.
    Blood; 1996 Mar 15; 87(6):2476-85. PubMed ID: 8630414
    [Abstract] [Full Text] [Related]

  • 13. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
    Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, Miyakuni T, Nakao S, Kishi K, Kubonishi I, Dan K, Fujita S.
    Blood; 1998 Nov 01; 92(9):3355-61. PubMed ID: 9787173
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
    Cebo C, Voutsadakis IA, Da Rocha S, Bourhis JH, Jalil A, Azzarone B, Turhan AG, Chelbi-Alix M, Chouaib S, Caignard A.
    Cancer Res; 2005 Apr 01; 65(7):2914-20. PubMed ID: 15805294
    [Abstract] [Full Text] [Related]

  • 17. Chronic myeloid leukemia as an immunological target.
    Lim SH, Coleman S.
    Am J Hematol; 1997 Jan 01; 54(1):61-7. PubMed ID: 8980262
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
    Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, Caillat-Zucman S, Bernheim A, Turhan AG, Caignard A, Zitvogel L.
    Cancer Res; 2005 Jul 15; 65(14):6409-17. PubMed ID: 16024645
    [Abstract] [Full Text] [Related]

  • 20. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
    Oka T, Sastry KJ, Nehete P, Schapiro SJ, Guo JQ, Talpaz M, Arlinghaus RB.
    Leukemia; 1998 Feb 15; 12(2):155-63. PubMed ID: 9519777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.